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### Background and aim

Pulmonary diseases are important causes of morbidity in both adults and children \[[@B1],[@B2]\]. The diverse pulmonary diseases go along with clinical challenges. In adults, lung cancer is one of the leading causes of death worldwide. It is often diagnosed at an advanced stage when successful treatment is difficult \[[@B3]\]. Furthermore, chronic obstructive pulmonary disease (COPD) and asthma are prevalent lung diseases that account for a major burden on society in terms of morbidity and health care costs. Early diagnosis and close monitoring of both diseases are important for proper treatment decisions, optimal disease control and prognosis. However, the available clinical tools are not always fulfilling. In young children, a reliable asthma diagnosis is difficult as there are no tools available to discriminate between true asthmatics and children with transient, virus-induced symptoms. On account of these clinical challenges, there is a continuous search for techniques that can improve accurate diagnoses and management decisions. A potential non-invasive technique is the analysis of volatile biomarkers in exhaled breath, so called volatile organic compounds (VOCs). In this manuscript we systematically review the current knowledge on VOCs regarding their potential clinical use in pulmonary diseases.

### The origin of exhaled volatile organic compounds

Asthma, COPD, Cystic Fibrosis (CF), and lung cancer are characterized by inflammation and oxidative stress. Monitoring of airway inflammation and oxidative stress can be helpful in the diagnosis and monitoring of these diseases. Current available techniques to directly measure inflammation and oxidative stress in the airways are bronchoscopy, bronchoalveolar lavage and biopsy. These techniques are too invasive for repeated routine use, especially in children. The need for non-invasive analysis of inflammation and oxidative stress in the lungs has led to increasing interest in exhaled breath analysis (Figure [1](#F1){ref-type="fig"}). Fractional exhaled Nitric Oxide (FeNO) is the most extensively studied marker in exhaled breath. Although the analysis of FeNO might be a helpful clinical tool in some pulmonary diseases, it has several limitations. For example in asthma, FeNO is especially a marker of allergic inflammation and therefore of limited use in non-allergic patients \[[@B4]\]. Consequently, additional exhaled biomarkers were studied. Next to non-volatile biomarkers that can be assessed in exhaled breath condensate, the analysis of exhaled VOCs gained popularity. VOCs are a diverse group of carbon-based chemicals that are volatile at room temperature. The source of exhaled VOCs can be exogenous or endogenous. Some VOCs can be taken up as pollutants from the environment via the skin or by inhalation or ingestion. Subsequently, these compounds are metabolized and exhaled. Other VOCs are formed in the body during several (patho)physiological processes \[[@B5],[@B6]\]. An important group of endogenously formed VOCs are hydrocarbons that are formed by lipid peroxidation. During the inflammatory process, Reactive Oxygen Species (ROS) are produced by inflammatory cells. Subsequently, ROS react with lipid membrane structures and cause degradation of polyunsaturated fatty acids. As a result several stable breakdown products including hydrocarbons are formed \[[@B5],[@B6]\]. Besides hydrocarbons, other VOCs can be identified, including nitrogen, oxygen or sulphur containing compounds. These VOCs can be formed by bacteria or during (patho)physiological processes in the liver, kidneys, and pancreas \[[@B5],[@B6]\]. As soon as VOCs are formed, they are either further oxidized into smaller components due to enhanced activity of enzymes (such as cytochrome P450 oxidase), or they directly enter the bloodstream \[[@B7]\]. Subsequently, VOCs are excreted into breath. Early findings of distinct VOCs in diseased people (e.g. with diabetes or cirrhosis) compared to healthy controls stimulated investigators to elucidate the clinical potential of exhaled VOCs in pulmonary diseases \[[@B5]\]. Since exhaled VOCs are formed during inflammatory processes, the analysis of VOCs may be a promising non-invasive technique to directly monitor inflammation and oxidative stress in the airways. This information might be of help in the diagnosis and monitoring of pulmonary diseases.

![**Techniques to assess airway inflammation and oxidative stress.** There are various methods to measure airway inflammation and oxidative stress ranging from completely non-invasive (exhaled breath analysis) to very invasive (open lung biopsy).](1465-9921-13-117-1){#F1}

### Technical analysis of exhaled breath

There are multiple techniques described to collect, detect, and analyze exhaled VOCs \[[@B6],[@B8],[@B9]\]. The most commonly used techniques are gas chromatography (GC), which is the gold standard, and the electronic nose (eNose). With the GC-technique, exhaled breath is firstly collected and temporarily stored (e.g. in inert bags or sorption tubes). After a desorption phase, individual VOCs can be assessed by GC usually followed by mass spectrometry (GC-MS) or flame ionization detection (GC-FID) \[[@B6]\]. The diverse VOCs are first separated based on their chemical properties and consecutively ionized and separated by their mass-to-charge (m/z) ratio (Figure [2](#F2){ref-type="fig"}). Breath samples can also be analyzed using an eNose \[[@B9]\]. The eNose consists of an array of nanosensors. When these sensors are exposed to a mixture of VOCs, a change in their electrical resistance is induced, leading to the production of a 'breath-print' (Figure [3](#F3){ref-type="fig"}). This breath-print represents the complex mixture of exhaled VOCs and can be used for pattern-recognition algorithms in multiple diseases \[[@B10]-[@B13]\]. A limitation of the eNose is that it is unable to analyze individual VOCs. In addition to GC and the eNose, other techniques that are used to study VOCs in pulmonary diseases include; proton transfer reaction mass spectrometry (PTR-MS), selected ion flow tube mass spectrometry (SIFT-MS), ion mobility spectrometry (IMS), laser spectroscopy, colorimetric sensor array, and gold nano particles sensors (GNPs).

![**Breath-print of VOCs by gas chromatography.** With the gas chromatography (GC) technique, exhaled breath is collected and temporarily stored in e.g. gas-tight syringes, glass bulbs, inert bags, or metal containers. Once the VOCs are collected and temporarily trapped, they can be released for analysis. This is often performed by solvent or thermal desorption. Subsequently, the analysis of individual molecular components can be assessed by GC usually followed by mass spectrometry (GC-MS) or flame ionization detection (GC-FID). The diverse VOCs are separated and quantified by using their specific compound characteristics. Distinct VOCs have dissimilar progression rates and reach the end of the GC column at different time points; the retention time. Based on their retention time, VOCs can be identified in a mass-spectra library. The figure demonstrates an example of a chromatogram of a breath sample analyzed with GC. The retention time (in minutes) is stated on the x axis, while the y axis shows the relative abundance of various compound signals. *Published in Robroeks* et al. *Pediatr Res 2010*\[[@B14]\].](1465-9921-13-117-2){#F2}

![**Breath-print of VOCs by the electronic Nose.** Breath samples can also be analyzed using an eNose. The eNose consists of an array of nanosensors. When these sensors are exposed to a mixture of VOCs, a change in their electrical resistance is induced, leading to the production of a 'breath-print'. This breath-print represents the complex mixture of exhaled VOCs and can be used for pattern-recognition algorithms in multiple diseases. A limitation of the eNose is that it is unable to analyze individual VOCs. In the figure two exhaled breath-prints analyzed with the eNose are demonstrated (purple line represents sample 1, green line represents sample 2). The y axis represents the change in resistance (Δ R/Rt = 0) of each of the 28 sensors (1--28). *Courtesy: Paul Brinkman, Niki Fens, Peter Sterk, University of Amsterdam, the Netherlands.*](1465-9921-13-117-3){#F3}

Materials and methods
=====================

Data sources and search criteria
--------------------------------

A systematic literature search was performed until July 2012 in PubMed, EMBASE, and the Cochrane Central Register of Controlled trials. Keywords/Mesh terms included: asthma, chronic obstructive pulmonary disease, COPD, cystic fibrosis, lung cancer, pulmonary disease, respiratory infection, combined with: volatile organic compounds, VOC, VOCs, exhaled breath or electronic nose. Reference lists were reviewed for additional references.

Study selection and data extraction
-----------------------------------

Figure [4](#F4){ref-type="fig"} illustrates a flow-chart of the study selection \[[@B16]\]. Controlled, clinical studies, with full text in English, exploring the diagnostic and monitoring value of VOCs in asthma, COPD, CF, lung cancer and respiratory tract infections were included. In vitro studies were excluded. Data on study design, setting, participant characteristics, VOCs techniques, and outcome measures were extracted. Due to expected heterogeneity of studies, no single scale was used for excluding studies on basis of quality. Instead, per study, criteria that are of importance to examine the validity are described in Table [1](#T1){ref-type="table"}.

![**Flow-chart of literature search.** Summary of evidence search and selection according to the Prisma flow-chart \[[@B16]\]. Abbreviations: VOCs = Volatile Organic Compounds.](1465-9921-13-117-4){#F4}

###### 

Characteristics of included studies on VOCs in pulmonary diseases

  **Author (year)**                  **Design**                                        **Comparison**                                      **Sample size**                                                                                                                        **Setting**                                                                                                                                                                                                        **Technique**                   **Outcome measure**                                       **Ref.**
  ---------------------------------- ------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------- --------------------------------------------------------- ------------------------
  Caldeira (2011)                    Cross-sectional                                   Asthma vs. controls                                 35 children with asthma, 15 healthy controls                                                                                           Hospital D. Pedro, Aveiro (Portugal)                                                                                                                                                                               GC-MS                           Set of 44 VOCs                                            \[[@B17]\]
  Caldeira (2012)                    Cross-sectional                                   Asthma vs. controls                                 32 children with allergic asthma, 27 healthy controls                                                                                  Hospital D. Pedro, Aveiro (Portugal)                                                                                                                                                                               GC-MS                           VOCs profile                                              \[[@B18]\]
  Dallinga (2010)                    Cross-sectional                                   Asthma vs. controls                                 63 children with asthma, 57 healthy controls                                                                                           Maastricht University MC                                                                                                                                                                                           GC-MS                           VOCs profile                                              \[[@B19]\]
  (the Netherlands)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Dragonieri (2007)                  Cross-sectional                                   Asthma vs. controls                                 10 patients with mild asthma, 10 patients with severe asthma, 20 healthy controls                                                      Leiden University MC (the Netherlands)                                                                                                                                                                             eNose                           VOCs profile                                              \[[@B10]\]
  Ibrahim (2011)                     Cross-sectional                                   Asthma vs. controls                                 35 patients with asthma, 23 healthy controls                                                                                           Wythenshawe Hospital, Manchester (UK)                                                                                                                                                                              GC-MS                           VOCs profile                                              \[[@B20]\]
  Lärstad (2007)                     Cross-sectional                                   Asthma vs. controls                                 13 patients with asthma, 14 healthy controls                                                                                           Göteborg University (Sweden)                                                                                                                                                                                       GC-FID                          Ethane, Pentane, Isoprene                                 \[[@B21]\]
  Montuschi (2010)                   Cross-sectional                                   Asthma vs. controls                                 27 patients with asthma, 24 healthy controls                                                                                           Istituto Dermopatico dell' Immacolata, Rome (Italy)                                                                                                                                                                eNose, GC-MS                    VOCs profile                                              \[[@B22]\]
  Olopade (1997)                     Cross-sectional Short follow-up in acute asthma   Asthma vs. controls                                 12 patients with acute asthma, 11 patients with stable asthma, 17 healthy controls                                                     University of Ilinois Hospital, Chicago (USA)                                                                                                                                                                      GC-FID                          Pentane                                                   \[[@B23]\]
  Paredi (2000)                      Cross-sectional                                   Asthma vs. controls                                 26 patients with asthma, 14 healthy controls                                                                                           National Heart and Lung Institute, Imperial College, London (UK)                                                                                                                                                   GC-FID                          Ethane                                                    \[[@B24]\]
  Basanta (2010)                     Cross-sectional                                   COPD vs. smokers                                    20 patients with COPD, 6 healthy smokers                                                                                               Wytenshawe Hospital, Manchester (UK)                                                                                                                                                                               GC-DMS                          VOCs profile                                              \[[@B25]\]
  Cristescu (2011)                   Cross-sectional                                   Emphysema vs. No emphysema                          204 (former) smokers (43 with emphysema/COPD)                                                                                          Radboud University, Nijmegen (the Netherlands)                                                                                                                                                                     PTR-MS                          Mass-spectra                                              \[[@B26]\]
  Fens (2009)                        Cross-sectional                                   COPD vs. asthma vs. controls                        30 patients with COPD, 20 patients with asthma, 20 non-smoking controls, 20 smoking controls                                           Academic MC Amsterdam; Haga Teaching Hospital, The Hague; Albert Schweitzer Hospital, Dordrecht (the Netherlands)                                                                                                  eNose                           VOCs profile                                              \[[@B15]\]
  Fens (2011)                        Cross-sectional                                   COPD vs. asthma                                     40 patients with COPD, 21 patients with fixed asthma, 39 patients with classic asthma                                                  Academic MC Amsterdam; Haga Teaching Hospital, The Hague; Albert Schweitzer Hospital, Dordrecht (the Netherlands)                                                                                                  eNose                           VOCs profile                                              \[[@B27]\]
  Hattesohl (2011)                   Cross-sectional Follow up after treatment         COPD vs. controls                                   10 patients with COPD with AAT deficiency, 23 patients with COPD without AAT deficiency, 10 healthy controls                           Phillipps University, Marburg (Germany)                                                                                                                                                                            eNose                           VOCs profile                                              \[[@B28]\]
  Hauschild (2012)                   Cross-sectional                                   COPD vs. controls                                   30 patients with COPD, 54 patients with COPD + BC, 35 healthy controls                                                                 Max Planck Institute for Informatics, Saarbrücken (Germany)                                                                                                                                                        IMS                             VOCs profile                                              \[[@B29]\]
  Paredi (2000)                      Cross-sectional                                   COPD vs. controls                                   22 patients with COPD, 14 healthy controls                                                                                             National Heart and Lung Institute, Imperial College, London (UK)                                                                                                                                                   GC-FID                          Ethane                                                    \[[@B30]\]
  Phillips (2012)                    Cross-sectional                                   COPD vs. controls                                   119 patients with COPD, 63 healthy controls                                                                                            Swansea University, Swansea (UK)                                                                                                                                                                                   GC-MS                           VOCs profile                                              \[[@B31]\]
  Timms (2012)                       Cross-sectional                                   COPD vs. asthma vs. controls                        17 patients with COPD, 20 patients with asthma, 7 healthy controls                                                                     University of New South Wales, Sydney (Australia)                                                                                                                                                                  eNose                           VOCs profile                                              \[[@B32]\]
  Van Berkel (2010)                  Cross-sectional                                   COPD vs. controls                                   66 patients with COPD, 15 steroid naïve COPD patients, 45 healthy controls                                                             Maastricht University MC (the Netherlands)                                                                                                                                                                         GC-MS                           VOCs profile                                              \[[@B33]\]
  Barker (2006)                      Cross-sectional                                   CF vs. controls                                     20 patients with CF, 20 healthy controls                                                                                               Aachen CF center (Germany)                                                                                                                                                                                         GC-MS                           Set of 12 VOCs                                            \[[@B34]\]
  Enderby (2009)                     Cross-sectional                                   CF vs. asthma                                       16 patients with CF, 21 patients with asthma                                                                                           University Hospital of North Staffordshire,Stoke-on-Trent (UK)                                                                                                                                                     SIFT-MS                         Hydrogen cyanide                                          \[[@B35]\]
  Gilchrist (2012)                   Cross-sectional                                   CF with- vs. CF without *Ps.* infection             8 CF patients with *Ps.* infection, 7 CF patients without *Ps.* infection                                                              University Hospital of North Staffordshire,Stoke-on-Trent (UK)                                                                                                                                                     SIFT-MS                         Hydrogen cyanide                                          \[[@B36]\]
  Kamboures (2005)                   Cross-sectional                                   CF vs. controls                                     20 patients with CF, 23 healthy controls                                                                                               University of California, Irvine (USA)                                                                                                                                                                             GC-MS                           Carbonyl sulphide, Dimethyl sulphide, Carbon disulphide   \[[@B37]\]
  McGrath (2000)                     Cross-sectional Follow up after treatment         CF during- vs. CF after exacerbation vs. controls   12 patients with CF, 12 healthy controls                                                                                               Queen's University, Belfast (UK)                                                                                                                                                                                   GC-MS                           Isoprene                                                  \[[@B38]\]
  Paredi (2000)                      Cross-sectional                                   CF vs. controls                                     23 patients with CF, 14 healthy controls                                                                                               National Heart and Lung Institute, Imperial College, London (UK)                                                                                                                                                   GC-FID                          Ethane                                                    \[[@B39]\]
  Robroeks (2010)                    Cross-sectional                                   CF vs. controls                                     48 patients with CF, 57 healthy controls                                                                                               Maastricht University MC (the Netherlands)                                                                                                                                                                         GC-MS                           VOCs profile                                              \[[@B14]\]
  Shestivska (2011)                  Cross-sectional                                   CF vs. controls                                     28 patients with CF, 9 healthy controls                                                                                                Academy of Science of the Czech Republic, Prague (Czech Republic)                                                                                                                                                  GC-MS                           Methyl thiocyanate                                        \[[@B40]\]
  Bajtarevic (2009)                  Cross-sectional                                   LC vs. controls                                     285 patients with LC, 472 healthy controls                                                                                             Innsbruck Medical University (Austria)                                                                                                                                                                             PTR-MS, GC-MS                   VOCs profile                                              \[[@B41]\]
  Buszewski (2012)                   Cross-sectional                                   LC vs. controls                                     29 patients with LC, 44 healthy controls                                                                                               Nicolaus Copernicus University, Torun (Poland)                                                                                                                                                                     GC-MS                           Set of multiple VOCs                                      \[[@B42]\]
  Crohns (2009)                      Cross-sectional Follow up after treatment         LC vs. controls                                     11 patients with LC, 30 healthy controls                                                                                               Tampere University Hospital (Finland)                                                                                                                                                                              GC-MS                           Pentane                                                   \[[@B43]\]
  D'Amico (2010)                     Cross-sectional                                   LC vs. no LC vs. controls                           28 patients with LC, 28 patients with diverse lung diseases (e.g. COPD (n = 16), bronchitis), 36 healthy controls                      C. Forlanini Hospital, Rome (Italy)                                                                                                                                                                                eNose (GC-MS)                   VOCs profile                                              \[[@B44]\]
  Di Natale (2003)                   Cross-sectional                                   LC vs. controls                                     35 patients with LC, 9 post-surgical LC patients, 18 healthy controls                                                                  C. Forlanini Hospital, Rome (Italy)                                                                                                                                                                                eNose (GC-MS)                   VOCs profile                                              \[[@B11]\]
  Dragonieri (2009)                  Cross-sectional                                   LC vs. COPD vs. controls                            10 patients with NSCLC, 10 patients with COPD, 10 healthy controls                                                                     Leiden University MC (the Netherlands)                                                                                                                                                                             eNose                           VOCs profile                                              \[[@B12]\]
  Fuchs (2010)                       Cross-sectional                                   LC vs. controls                                     12 patients with LC, 12 healthy smokers, 12 healthy controls                                                                           University Rostock (Germany)                                                                                                                                                                                       GC-MS                           Set of 10 volatile aliphatic aldehydes                    \[[@B45]\]
  Gaspar (2009)                      Cross-sectional                                   LC vs. controls                                     18 patients with LC, 10 healthy controls                                                                                               University of Lisbon (Portugal)                                                                                                                                                                                    GC-MS                           VOCS profile                                              \[[@B46]\]
  Gordon (1985)                      Cross-sectional                                   LC vs. controls                                     12 patients with LC, 9 healthy controls                                                                                                Michael Reese Hospital, Chicago (USA)                                                                                                                                                                              GC-MS                           Set of 22 VOCs                                            \[[@B47]\]
  Kischkel (2010)                    Cross-sectional                                   LC vs. controls                                     31 patients with LC, 31 healthy smokers, 31 healthy controls                                                                           University of Rostock (Germany)                                                                                                                                                                                    GC-MS                           Set of 42 VOCs                                            \[[@B48]\]
  Ligor (2009)                       Cross-sectional                                   LC vs. controls                                     65 patients with LC, 31 healthy controls                                                                                               Innsbruck Medical University (Austria)                                                                                                                                                                             GC-MS                           Set of 103 VOCs                                           \[[@B49]\]
  Machado (2005)                     Cross-sectional                                   LC vs. no LC vs. controls                           28 patients with LC, 57 patients with diverse lung diseases (e.g. COPD (n = 12), asthma (n = 11), CBD), 50 healthy controls            Cleveland Clinic (USA)                                                                                                                                                                                             eNose (GC-MS)                   VOCs profile                                              \[[@B13]\]
  Mazzone (2007)                     Cross-sectional                                   LC vs. no LC vs. controls                           49 patients with NSCLC, 73 patients with diverse lung diseases (e.g. COPD (n = 18), sarcoidosis), 21 healthy controls                  Cleveland Clinic (USA)                                                                                                                                                                                             Colorimetric sensor array       VOCs profile                                              \[[@B50]\]
  Mazzone (2012)                     Cross-sectional                                   LC vs. controls                                     92 patients with LC, 59 healthy smokers, 78 patients with diverse lung diseases (e.g. COPD (n = 8))                                    Cleveland Clinic (USA)                                                                                                                                                                                             Colorimetric sensor array       VOCs profile                                              \[[@B51]\]
  Peng (2009)                        Cross-sectional                                   LC vs. controls                                     40 patients with LC, 56 healthy controls                                                                                               Rambam Health Care Campus, Haifa (Israel)                                                                                                                                                                          GNPs GC-MS                      VOCs profile                                              \[[@B52]\]
  Peng (2010)                        Cross-sectional                                   LC vs. controls                                     30 patients with PLC, 22 healthy controls                                                                                              Rambam Health Care Campus, Haifa (Israel)                                                                                                                                                                          GNPs GC-MS                      VOCs profile                                              \[[@B53]\]
  Phillips (1999)                    Cross-sectional                                   LC vs. no LC                                        108 patients with abnormal chest radiograph (60 patients with LC)                                                                      Penn State MC, Hershey (USA); Hammersmith Hospital, London (UK); St. Vincent's MC, New York (USA)                                                                                                                  GC-MS                           VOCs profile                                              \[[@B54]\]
  Phillips (2003)                    Cross-sectional                                   LC vs. no LC vs. controls                           178 patients with abnormal chest radiograph (87 patients with LC), 41 healthy controls                                                 Charing Cross Hospital, London (UK); Columbia Presbyterian MC/New York University MC/St. Vincent's MC, New York (USA); Penn State MC, Hershey (USA)                                                                GC-MS                           VOCs profile                                              \[[@B7]\]
  Phillips (2007--2008)              Cross-sectional                                   LC vs. controls                                     193 patients with PLC, 211 (former) healthy smokers                                                                                    Harper Hospital, Detroit; New York University MC/Columbia University MC/Weill Medical College of Cornell University, New York (USA); University of California, Los Angeles; Danbury Hospital, Connecticut (USA).   GC-MS                           VOCs profile                                              \[[@B55]\], \[[@B56]\]
  Poli (2005)                        Cross-sectional Short follow-up in LC             LC vs. COPD vs. controls                            36 patients with NSCLC, 25 patients with COPD, 35 healthy smokers, 50 healthy non-smokers                                              University of Parma (Italy)                                                                                                                                                                                        GC-MS                           Set of 13 VOCs                                            \[[@B57]\]
  Poli (2008)                        Follow-up                                         LC before vs. after surgery                         36 patients with NSCLC, 50 healthy controls                                                                                            University of Parma (Italy)                                                                                                                                                                                        GC-MS                           Set of 12 VOCs                                            \[[@B58]\]
  Poli (2010)                        Cross-sectional                                   LC vs. controls                                     40 patients with NSCLC, 38 healthy controls                                                                                            University of Parma (Italy)                                                                                                                                                                                        GC-MS                           Set of 7 aldehydes                                        \[[@B59]\]
  Preti (1988)                       Cross-sectional                                   LC vs. controls                                     10 patients with LC, 16 healthy controls                                                                                               University Hospital Pennsylvania, Philadelphia (USA)                                                                                                                                                               GC-MS                           Aniline, o-Toluidine                                      \[[@B60]\]
  Rudnicka (2011)                    Cross-sectional                                   LC vs. controls                                     23 patients with LC, 30 healthy controls                                                                                               Nicolaus Copernicus University, Torun (Poland)                                                                                                                                                                     GC-MS                           Set of 55 VOCs                                            \[[@B61]\]
  Skeldon (2006)                     Cross-sectional                                   LC vs. no LC vs. controls                           12 patients with LC, 40 patients with diverse lung diseases, 58 healthy controls                                                       Ninewells Hospital, Dundee (UK)                                                                                                                                                                                    Laser absorption spectroscopy   Ethane                                                    \[[@B62]\]
  Song (2010)                        Cross-sectional                                   LC vs. controls                                     43 patients with NSCLC, 41 healthy controls                                                                                            Anhui Medical University, Hefei, Anhui (China)                                                                                                                                                                     GC-MS                           1-butanol, 3-hydroxy-2-butanone                           \[[@B63]\]
  Steeghs (2007)                     Cross-sectional                                   LC vs. controls                                     11 patients with LC, 57 healthy smokers                                                                                                Radboud University, Nijmegen (the Netherlands)                                                                                                                                                                     PTR-MS                          Mass-spectra                                              \[[@B64]\]
  Ulanowska (2011)                   Cross-sectional                                   LC vs. controls                                     137 patients with LC, 143 healthy controls                                                                                             Nicolaus Copernicus University, Torun (Poland)                                                                                                                                                                     GC-MS                           VOCs profile                                              \[[@B65]\]
  Wehinger (2007)                    Cross-sectional                                   LC vs. controls                                     17 patients with PLC, 170 healthy controls                                                                                             Innsbruck Medical University (Austria)                                                                                                                                                                             PTR-MS                          Mass-spectra                                              \[[@B66]\]
  Westhoff (2009)                    Cross-sectional                                   LC vs. controls                                     32 patients with LC, 54 healthy controls                                                                                               Hemer Lung Hospital (Germany)                                                                                                                                                                                      IMS                             VOCs profile                                              \[[@B67]\]
  Chapman (2012)                     Cross-sectional                                   MPM vs. ARD vs. controls                            20 patients with MPM, 18 patients with ARD, 42 healthy controls                                                                        St Vincent and Prince of Wales Hospital, Sydney (Australia)                                                                                                                                                        eNose                           VOCs profile                                              \[[@B68]\]
  Gennaro (2010) Dragonieri (2012)   Cross-sectional                                   MPM vs. no MPM                                      13 patients with MPM, 13 subjects with long-term asbestos exposure, 13 healthy controls                                                University of Bari Aldo Moro, Bari (Italy)                                                                                                                                                                         eNose, GC-MS                    VOCs profile                                              \[[@B69]\], \[[@B70]\]
  Chambers (2009)                    Cross-sectional                                   A. fumigatus vs. controls                           32 patients with diverse lung diseases (e.g. asthma (n = 11), CF (n = 6), COPD (n = 3), 10 neutropenic patients, 14 healthy controls   University of Christchurch (New Zealand)                                                                                                                                                                           GC-MS                           2-Pentylfuran                                             \[[@B71]\]
  Hanson (2005)                      Cross-sectional                                   VAP vs. no VAP                                      19 patients with + VAP score, 19 patients with - VAP score                                                                             University of Pennsylvania, Philadelphia (USA)                                                                                                                                                                     eNose                           VOCs profile                                              \[[@B72]\]
  Hockstein (2004)                   Cross-sectional                                   VAP vs. no VAP                                      13 ventilated patients with VAP, 12 ventilated patients without VAP                                                                    University of Pennsylvania, Philadelphia (USA)                                                                                                                                                                     eNose                           VOCs profile                                              \[[@B73]\]
  Hockstein (2005)                   Cross-sectional                                   VAP vs. no VAP                                      15 patients with + VAP score, 29 patients with - VAP score                                                                             University of Pennsylvania, Philadelphia (USA)                                                                                                                                                                     eNose                           VOCs profile                                              \[[@B74]\]
  Kanoh (2005)                       Cross-sectional Short follow-up in ILD patients   ILD vs. controls                                    34 patients with ILD, 16 healthy controls                                                                                              National Defense Medical College, Saitama (Japan)                                                                                                                                                                  GC-FID                          Ethane                                                    \[[@B75]\]
  Kolk (2012)                        Cross-sectional                                   TB vs. no TB                                        171 patients suspected of TB                                                                                                           Royal Tropical Institute, Amsterdam (the Netherlands); Desmond Tutu TB Centre, Cape Town (South Africa)                                                                                                            GC-MS                           VOCs profile                                              \[[@B76]\]
  Phillips (2007)                    Cross-sectional                                   TB vs. no TB vs. controls                           42 patients suspected of TB, 59 healthy controls                                                                                       Bellevue Hospital, New York (USA)                                                                                                                                                                                  GC-MS                           VOCs profile                                              \[[@B77]\]
  Phillips (2010)                    Cross-sectional                                   TB vs. no TB                                        226 patients suspected of TB                                                                                                           University of California, San Diego (USA); University of Santo Tomas, Manila (Philippines), De La Salle University Hospital, Cavite (Philippines), East London Tuberculosis Service (UK)                           GC-MS                           VOCs profile                                              \[[@B78]\]
  Phillips (2012)                    Cross-sectional                                   TB vs. controls                                     130 patients with TB, 121 healthy controls                                                                                             University of Santo Tomas, Manila (Philippines); De La Salle University Hospital, Cavite (Philippines); Homerton University Hospital, London (UK); Hinduja Hospital, Mumbai (India)                                GC-SAW                          VOCs profile                                              \[[@B79]\]
  Syhre (2009)                       Cross-sectional                                   TB vs. controls                                     10 patients with TB, 10 healthy controls                                                                                               Otago University, Christchurch (New Zealand); Modilon Hospital, Madang (Papua New Guinea)                                                                                                                          GC-MS                           Methyl nicotinate                                         \[[@B80]\]
  Scholpp (2002)                     Cross-sectional                                   Critically ill patients vs. controls                65 critically ill patients (n = 19 with head injury, n = 13 with ARDS, n = 33 at risk of ARDS), 10 healthy controls                    University Hospital of Freiburg (Germany)                                                                                                                                                                          GC-FID, GC-MS                   Acetone Isoprene, n-Pentane                               \[[@B81]\]
  Schubert (1998)                    Cross-sectional Short follow-up in VAP patients   ARDS vs. no ARDS                                    19 critically ill patients with ARDS, 18 critically ill patients without ARDS                                                          University Hospital of Freiburg (Germany)                                                                                                                                                                          GC-FID, GC-MS                   Acetone Isoprene, n-Pentane                               \[[@B82]\]

**Abbreviations:** AAT deficiency = Alpha 1-antitrypsin deficiency; A. fumigatus = Aspergillus fumigatus; ARD = Benign Asbestos-Related Diseases; ARDS = Acute Respiratory Distress Syndrome; BC = Bronchial Carcinoma; CBD = Chronic pulmonary Beryllium Disease; CF = Cystic Fibrosis; Classic asthma = Asthmatics with reversible airway obstruction; COPD = Chronic Obstructive Pulmonary Disease; DMS = Differential Mobility Spectrometry; eNose = electronic Nose; FID = Flame Ionization Detector; Fixed asthma = Asthmatics with fixed airway obstruction; GC = Gas Chromatography; GNPs = Gold Nano Particles sensors; ILD = Interstitial Lung Disease (e.g. sarcoidosis, idiopathic pulmonary fibrosis, cryptogenic organizing pneumonia); IMS = Ion Mobility Spectrometry; LC = Lung Cancer; MC = Medical Centre; MPM = Malignant Pleural Mesothelioma; MS = Mass Spectrometry; NSCLC = Non-Small Cell Lung Cancer; OFD = On-Fiber-Derivatization; *P*. infection = *Pseudomonas aeruginosa* infection; PLC = Primary Lung Cancer; PTR-MS = Proton Transfer Reaction Mass Spectrometry; Ref. = Reference; SAW = surface acoustic wave; SIFT-MS = Selected Ion Flow Tube Mass Spectrometry; TB = pulmonary Tuberculosis; VAP = Ventilator Associated-Pneumonia; VOCs = Volatile Organic Compounds.

Data synthesis and analysis
---------------------------

Evidence data were pooled by study design; studies using: 1) single VOCs in diagnosing pulmonary diseases (Table [2](#T2){ref-type="table"}); 2) VOCs profiles in diagnosing pulmonary diseases (Table [3](#T3){ref-type="table"}); and 3) VOCs profiles in differential diagnosing pulmonary diseases (Table [4](#T4){ref-type="table"}).

###### 

Studies using single VOCs for the diagnosis of various pulmonary diseases (diseased vs. healthy controls)

  **Author (year)**                                                           **Marker**              **Disease**                   **N**                  **Value**             **Unit**            **Diff.**             **Value marker**      **Unit**            **Controls**   **N**        **p-value**   **Ref.**
  --------------------------------------------------------------------------- ----------------------- ----------------------------- ---------------------- --------------------- ------------------- --------------------- --------------------- ------------------- -------------- ------------ ------------- ------------
  Lärstad (2007)                                                              Ethane                  Asthma                        13                     N.S.                                      =                     N.S.                                      Controls       14           p \> 0.05     \[[@B21]\]
  Pentane                                                                                                                           N.S.                                         =                   N.S.                                                                           p \> 0.05                  
  Isoprene                                                                                                                          113                    ppb^∞^                \<                  143                   ppb^∞^                                                   p \< 0.05                  
  Olopade (1997)                                                              Pentane                 Acute asthma                  12                     8.4 ± 2.9             nmol/L\*            \>                    2.6 ± 0.2             nmol/L\*            Controls       17           p \< 0.05     \[[@B23]\]
  Pentane                                                                     Stable asthma           11                            3.6 ± 0.4              nmol/L\*              =                   2.6 ± 0.2             nmol/L\*              Controls            17             p \> 0.05                  
  Paredi (2000)                                                               Ethane\*\*              Steroid naïve asthma          12                     2.06 ± 0.30           ppb\*               \>                    0.88 ± 0.09           ppb\*               Controls       14           p \< 0.01     \[[@B24]\]
  Paredi (2000)                                                               Ethane\*\*              Steroid naïve COPD            12                     2.77 ± 0.25           ppb\*               \>                    0.88 ± 0.09           ppb\*               Controls       14           p \< 0.05     \[[@B30]\]
  Barker (2006)                                                               Pentane\*\*             CF                            20                     0.36 (0.24-0.48)      ppb^\#^             \>                    0.21 (0.13-0.29)      ppb^\#^             Controls       20           p \< 0.05     \[[@B34]\]
  Dimethyl Sulphide\*\*                                                                                                             3.89 (2.24-5.54)       ppb^\#^               \<                  7.58 (5.73-9.43)      ppb^\#^                                                  p \< 0.01                  
  Ethane\*\*                                                                                                                        0.39 (−0.04-0.82)      ppb^\#^               =                   0.10 (−0.25-0.44)     ppb^\#^                                                  p \> 0.05                  
  Propane, methanol, ethanol, acetone, isoprene, benzene, toluene, limonene                                                         \-                                           =                   \-                                                                             p \> 0.05                  
  Kamboures (2005)                                                            Carbonyl sulphide\*\*   CF                            20                     \- 110 ± 60           pptv^\#^            \>                    \- 250 ± 20           pptv^\#^            Controls       23           p \< 0.001    \[[@B37]\]
  Dimethyl sulphide                                                                                                                 4,780 ± 1,350          pptv^\#^              =                   3,920 ± 680           pptv^\#^                                                 p \> 0.05                  
  Carbon sulphide\*\*                                                                                                               26 ± 38                pptv^\#^              \>                  \- 17 ± 15            pptv^\#^                                                 p \< 0.05                  
  McGrath (2000)                                                              Isoprene                CF during exacerbation        12                     125 ± 23              pmol·min·kg^-1^\*   \<                    164 ± 20              pmol·min·kg^-1^\*   Controls       12           p \< 0.05     \[[@B38]\]
  Isoprene                                                                    CF after exacerbation   12                            188 ± 23               pmol·min·kg^-1^\*     =                   164 ± 20              pmol·min·kg^-1^\*     Controls            12             p \> 0.05                  
  Paredi (2000)                                                               Ethane\*\*              Steroid naïve CF              23                     1.99 ± 0.20           ppb\*               \>                    0.82 ± 0.09           ppb\*               Controls       14           p \< 0.05     \[[@B39]\]
  Shestivska (2011)                                                           Methyl thiocyanate      CF                            28                     7 (2--21)             ppbv^\~^            =                     8 (5--8)              ppbv°°              Controls       9            p \> 0.05     \[[@B40]\]
  Bajtarevic (2009)                                                           Isoprene                LC                            220                    81.5                  ppb^∞^              \<                    105.2                 ppb^∞^              Controls       441          p \< 0.01     \[[@B41]\]
  Acetone                                                                                                                           458.7                  ppb^∞^                \<                  627.5                 ppb^∞^                                                   p \< 0.01                  
  Methanol                                                                                                                          118.5                  ppb^∞^                \<                  142.0                 ppb^∞^                                                   p \< 0.05                  
  Buszewski (2012)                                                            Acetone                 LC                            29                     34.57-390.60          ppb°                ?                     44.20-531.45          ppb°                Controls       44           p \< 0.05     \[[@B42]\]
  Benzene                                                                                                                           1.29-3.82              ppb°                  ?                   1.38-14.97            ppb°                                                     p \< 0.05                  
  Butanal                                                                                                                           1.32-2.55              ppb°                  \>                  1.35-1.87             ppb°                                                     p \< 0.01                  
  2-Butanone                                                                                                                        1.35-2.86              ppb°                  ?                   1.35-3.18             ppb°                                                     p \< 0.01                  
  Ethyl acetate                                                                                                                     3.98-22.89             ppb°                  \>                  1.12-8.22             ppb°                                                     p \< 0.01                  
  Ethyl benzene                                                                                                                     1.45-3.16              ppb°                  ?                   2.22-18.38            ppb°                                                     p \< 0.01                  
  2-Pentanone                                                                                                                       3.25-8.77              ppb°                  \>                  1.80-4.11             ppb°                                                     p \< 0.01                  
  Propanal                                                                                                                          1.56-3.74              ppb°                  \>                  1.56-3.44             ppb°                                                     p \< 0.01                  
  1-Propanol                                                                                                                        4.37-13.15             ppb°                  \>                  N.S.                  ppb°                                                     p \< 0.01                  
  2-Propanol                                                                                                                        3.32-7.19              ppb°                  \>                  3.21-4.17             ppb°                                                     p \< 0.01                  
  2-Propenal                                                                                                                        6.84-94.36             ppb°                  \>                  5.10-9.57             ppb°                                                     p \< 0.05                  
  Other VOCs                                                                                                                        N.S.                   ppb°                  =                   N.S.                  ppb°                                                     p \> 0.05                  
  Crohns (2009)                                                               Pentane\*\*             LC                            11                     1.73 (1.05-2.86)      ng/L^\#^            \>                    0.83 (0.61-1.13)      ng/L^\#^            Controls       30           p \< 0.05     \[[@B43]\]
  Fuchs (2010)                                                                Pentanal\*\*            LC                            12                     0.019 (0.011-0.031)   nmol/Lˆ             \>                    0.002 (0.000-0.011)   nmol/Lˆ             Controls       12           p \< 0.05     \[[@B45]\]
  Hexanal\*\*                                                                                                                       0.010 (0.008-0.026)    nmol/Lˆ               \>                  0.000 (0.000-0.001)   nmol/Lˆ                                                  p \< 0.05                  
  Octanal\*\*                                                                                                                       0.052 (0.026-0.087)    nmol/Lˆ               \>                  0.011 (0.004-0.028)   nmol/Lˆ                                                  p \< 0.05                  
  Nonanal\*\*                                                                                                                       0.239 (0.128-0.496)    nmol/Lˆ               \>                  0.033 (0.021-0.096)   nmol/Lˆ                                                  p \< 0.05                  
  Acetaldehyde\*\*, Propanal, butanal\*\*, heptanal, decanal\*\*                                                                    \-                                           =                   \-                                                                             p \> 0.05                  
  Kischkel (2010)                                                             Dimethyl sulphide\*\*   LC                            31                     0.27 (0.00-0.27)      nmol/Lˆ             \<                    0.30 (0.00-0.31)      nmol/Lˆ             Controls       31           p \< 0.01     \[[@B48]\]
  Dimethyl formamide\*\*                                                                                                            1855 (0.00-3340.88)    (counts)ˆ             \>                  0.00 (0.00-2954.13)   (counts)ˆ                                                p \< 0.05                  
  Butane\*\*                                                                                                                        0.00 (0.00-0.11)       nmol/Lˆ               \>                  0.18 (0.00-0.52)      nmol/Lˆ                                                  p \< 0.01                  
  Butanal\*\*                                                                                                                       1.07 (0.38-3.51)       nmol/Lˆ               \>                  0.32 (0.00-1.40)      nmol/Lˆ                                                  p \< 0.001                 
  Other VOCs (N = 38)                                                                                                               N.S.                                                             N.S                                                                            p \> 0.05                  
  Poli (2005)                                                                 2-Methylpentane         NSCLC                         36                     139.5 (65.7-298.8)    10^-12^Mˆ           \>                    27.7 (3.4-50.3)       10^-12^Mˆ           Controls       50           p \< 0.001    \[[@B57]\]
  Pentane                                                                                                                           647.5 (361.3-1112.5)   10^-12^Mˆ             \>                  268.0 (107.7-462.7)   10^-12^Mˆ                                                p \< 0.001                 
  Ethylbenzene                                                                                                                      24.0 (13.6-32.6)       10^-12^Mˆ             \>                  13.6 (10.8-15.1)      10^-12^Mˆ                                                p \< 0.01                  
  Xylenes                                                                                                                           68.9 (43.6-108.4)      10^-12^Mˆ             \>                  31.1 (21.1-56.4)      10^-12^Mˆ                                                p \< 0.001                 
  Trimethylbenzene                                                                                                                  14.9 (9.3-22.1)        10^-12^Mˆ             \>                  6.2 (4.7-11.0)        10^-12^Mˆ                                                p \< 0.01                  
  Toluene                                                                                                                           158.8 (118.7-237.5)    10^-12^Mˆ             \>                  80.8 (58.9-140.0)     10^-12^Mˆ                                                p \< 0.001                 
  Benzene                                                                                                                           94.5 (62.2-132.2)      10^-12^Mˆ             \>                  44.7 (27.7-68.6)      10^-12^Mˆ                                                p \< 0.001                 
  Decane                                                                                                                            568.0 (277.9-1321.6)   10^-12^Mˆ             \>                  208.7 (14.3-405.5)    10^-12^Mˆ                                                p \< 0.001                 
  Octane                                                                                                                            61.0 (22.4-112.9)      10^-12^Mˆ             \>                  20.2 (4.0-50.8)       10^-12^Mˆ                                                p \< 0.001                 
  Pentamethylheptane                                                                                                                2.5 (1.2-9.7)          10^-12^Mˆ             \>                  0.9 (0.1-2.6)         10^-12^Mˆ                                                p \< 0.001                 
  Isoprene, heptane, styrene                                                                                                        \-                                           =                   \-                                                                             p \> 0.05                  
  Poli (2008)                                                                 2-Methylpentane         NSCLC (3 yrs after surgery)   10                     87.9 (35.5-278.9)     10^-12^Mˆ           \>                    27.7 (3.4-50.3)       10^-12^Mˆ           Controls       50           p \< 0.05     \[[@B58]\]
  Pentane                                                                                                                           1569.0 (497.9-3214)    10^-12^Mˆ             \>                  268.0 (107.7-462.7)   10^-12^Mˆ                                                p \< 0.001                 
  Ethylbenzene                                                                                                                      46.4 (38.6-90.9)       10^-12^Mˆ             \>                  13.6 (10.8-15.1)      10^-12^Mˆ                                                p \< 0.001                 
  Xylenes                                                                                                                           56.2 (38.9-80.4)       10^-12^Mˆ             \>                  31.1 (21.1-56.4)      10^-12^Mˆ                                                p \< 0.05                  
  Trimethylbenzene                                                                                                                  15.3 (11.7-22.3)       10^-12^Mˆ             \>                  6.2 (4.7-11.0)        10^-12^Mˆ                                                p \< 0.001                 
  Toluene                                                                                                                           297 (202.6-297.0)      10^-12^Mˆ             \>                  80.8 (58.9-140.0)     10^-12^Mˆ                                                p \< 0.001                 
  Pentamethylheptane                                                                                                                8.8 (2.2-15.2)         10^-12^Mˆ             \>                  0.9 (0.1-2.6)         10^-12^Mˆ                                                p \< 0.001                 
  Isoprene                                                                                                                          678.9 (359.8-1111.0)   10^-12^Mˆ             \<                  3789 (1399--6589)     10^-12^Mˆ                                                p \< 0.01                  
  Benzene, Heptane, Octane, Styrene                                                                                                 \-                                           =                   \-                                                                             p \> 0.05                  
  Preti (1988)                                                                O-toluidine             LC                            10                     N.S                                       \>                    N.S                                       Controls       16           p \< 0.05     \[[@B60]\]
  Aniline                                                                                                                           N.S                                          =                   N.S                                                                            p \> 0.05                  
  Rudnicka (2011)                                                             Propane                 LC                            23                     3.19-9.74             ppb°                \>                    3.45-5.96             ppb°                Controls       30           p \< 0.05     \[[@B61]\]
  2-Propenal                                                                                                                        N.S                                          ?                   N.S                                                                            p \< 0.05                  
  Carbon disulfide                                                                                                                  N.S                                          ?                   N.S                                                                            p \< 0.05                  
  Isopropyl alcohol                                                                                                                 N.S                                          ?                   N.S                                                                            p \< 0.05                  
  Ethylbenzene                                                                                                                      1.45--3.16             ppb°                  \<                  2.22--18.38           ppb°                                                     p \< 0.05                  
  Styrene                                                                                                                           N.S                                          ?                   N.S                                                                            p \< 0.05                  
  Other VOCs (N = 49)                                                                                                               N.S                                          =                   N.S                                                                            p \> 0.05                  
  Skeldon (2006)                                                              Ethane\*\*              LC                            12                     0.7 (0--7.6)          ppb^\~^             =                     1.9 (0--10.54)        ppb^\~^             Controls       12           p \> 0.05     \[[@B62]\]
  Song (2010)                                                                 1-Butanol\*\*           NSCLC                         43                     6.36 (12.93)          ng/Lˆ               \>                    2.18 (2.06)           ng/Lˆ               Controls       41           p \< 0.001    \[[@B63]\]
  3-Hydroxy-2-butanone\*\*                                                                                                          8.28 (11.52)           ng/Lˆ                 \>                  1.29 (2.01)           ng/Lˆ                                                    p \< 0.001                 
  Ulanowska(2011)                                                             Ethanol\*\*             LC                            137                    466.9 (12.8-1520.1)   ppb°°               \>                    188.5 (4.5-479.5)     ppb°°               Controls       86           p \< 0.05     \[[@B65]\]
  Acetone\*\*                                                                                                                       358.6 (112.3-2653.7)   ppb°°                 \>                  225.7 (41.6-753.4)    ppb°°                                                    p \< 0.05                  
  Butane\*\*                                                                                                                        90.3 (6.1-421.3)       ppb°°                 \>                  56.2 (5.2-165.7)      ppb°°                                                    p \< 0.05                  
  Dimethyl sulphide\*\*                                                                                                             11.9 (6.3-18.5)        ppb°°                 \>                  9.3 (5.3-19.3)        ppb°°                                                    p \< 0.05                  
  Isoprene\*\*                                                                                                                      100.3 (19.2-295.5)     ppb°°                 \>                  70.8 (19.5-200.5)     ppb°°                                                    p \< 0.05                  
  Propanal\*\*                                                                                                                      7.8 (5.5-33.8)         ppb°°                 \>                  6.9 (5.6-9.1)         ppb°°                                                    p \< 0.05                  
  1-Propanol\*\*                                                                                                                    54.8 (5.4-473.3)       ppb°°                 \>                  6.6 (N.S.)            ppb°°                                                    p \< 0.05                  
  2-Pentanone\*\*                                                                                                                   7.5 (4.4-53.2)         ppb°°                 \>                  4.8 (4.6-5.1)         ppb°°                                                    p \< 0.05                  
  Furan\*\*                                                                                                                         4.7 (3.1-7.0)          ppb°°                 \>                  3.7 (3.0-5.3)         ppb°°                                                    p \< 0.05                  
  o-Xylene\*\*                                                                                                                      22.1 (7.6-95.2)        ppb°°                 \>                  17.4 (6.2-30.8)       ppb°°                                                    p \< 0.05                  
  Ethylbenzene\*\*                                                                                                                  19.6 (4.6-89.3)        ppb°°                 \>                  10.4 (8.6-14.0)       ppb°°                                                    p \< 0.05                  
  Other VOCs (N ≈ 20)                                                                                                               \-                                           =                   \-                                                                             p \> 0.05                  
  Wehinger (2007)                                                             Formaldehyde            PLC                           17                     7.0 (15.5)            ppbˆ                \>                    3.0 (1.9)             ppbˆ                Controls       170          p \< 0.001    \[[@B66]\]
  Propanol                                                                                                                          244.1 (236.2)          ppbˆ                  \>                  94.1 (55.2)           ppbˆ                                                     p \< 0.001                 
  Isoprene                                                                                                                          52.1 (26.7)            ppbˆ                  \<                  81.8 (56.1)           ppbˆ                                                     p \< 0.01                  
  Acetone, o-Toluidine                                                                                                              \-                                           =                   \-                                                                             p \> 0.05                  
  Gennaro (2010)                                                              Cyclohexane\*\*         MPM                           13                     251.79 (84%)          ng/L^∂^             \>                    33.08 (58%)           ng/L^∂^             Controls       13           p \< 0.05     \[[@B70]\]
  Other VOCs (N = 19)                                                                                                               \-                                           =                   \-                                                                             p \> 0.05                  
  Syhre (2009)                                                                Methyl nicotinate       TB                            10                     N.S                                       \>                    N.S                                       Controls       10           p \< 0.01     \[[@B80]\]
  Chambers (2009)                                                             2-Pentylfuran\*\*\*     A. fumigatus                  17                     Sens: 77, Spec: 78    \%                  \>                    Not detected                              Controls       14           N.S.          \[[@B71]\]
  Kanoh (2005)                                                                Ethane\*\*              ILD                           34                     8.5 ± 8.0             pmol/dL\*           \>                    2.9 ± 1.0             pmol/dL\*           Controls       16           p \< 0.001    \[[@B75]\]
  Scholpp (2002)                                                              Acetone                 ARDS                          13                     50.0 (19.6-72.3)      nmol/Lˆ             =                     33.2 (20.8-38.6)      nmol/Lˆ             Controls       10           p \> 0.05     \[[@B81]\]
  Isoprene                                                                                                                          2.18 (1.1-3.89)        nmol/L^\#^            \<                  5.99 (3.53-8.45)      nmol/L^\#^                                               p \< 0.05                  
  n-Pentane                                                                                                                         1.00 (0.26-1.72)       nmol/Lˆ               \>                  0.12 (0.10-0.16)      nmol/Lˆ                                                  p \< 0.05                  
  n-Pentane                                                                   At risk ARDS            33                            0.49 (0.30-0.99)       nmol/Lˆ               \>                  0.12 (0.10-0.16)      nmol/Lˆ               Controls            10             p \< 0.05                  
  Schubert (1998)                                                             Acetone                 ARDS                          19                     149 (113--485)        nmol/m^2\ ≈^        =                     119 (52--270)         nmol/m^2≈^          No ARDS        18           p \> 0.05     \[[@B82]\]
                                                                              Isoprene                                                                     9.8 (8.2-21.6)        nmol/m^2\ ≈^        \<                    21.8 (13.9-41.4)      nmol/m^2≈^                                      p \< 0.05      
                                                                              n-Pentane                                                                    4.2 (3.7-9.3)         nmol/m^2\ ≈^        =                     5.1 (1.4-18.6)        nmol/m^2≈^                                      p \> 0.05      

Data are presented as; \*mean ± SEM or SD; ^\#^mean (95% confidence interval);^∞^median; ˆmedian (25^th^-75^th^ percentile); ^\~^median (range); ^≈^median (95% confidence interval); ° range; °° mean (range); ^∂^ median (relative standard deviation). \*\* Exhaled concentrations corrected for ambient concentrations (e.g. subtraction, VOCs filter). \*\*\* Sensitivity and specificity 2-Pentylfuran compared with gold standard (sputum). Diff. = Difference between diseased and controls: \> elevated in diseased vs. controls, = no difference in diseased vs. controls, \< decreased in diseased vs. controls. Abbreviations: A. fumigatus = Aspergillus fumigatus; ARDS = Acute Respiratory Distress Syndrome; CF = Cystic Fibrosis; COPD = Chronic Obstructive Pulmonary Disease; ILD = Interstitial Lung Disease (e.g. sarcoidosis, idiopathic pulmonary fibrosis, cryptogenic organizing pneumonia); LC = Lung Cancer; MPM = Malignant Pleural Mesothelioma; N = Sample size; N.S. = Not Stated; NSCLC = Non-Small Cell Lung Cancer; PLC = Primary Lung Cancer; Ref. = Reference.

###### 

Studies using VOCs profiles for the diagnosis of various pulmonary diseases (diseased vs. healthy controls)

  **Author (year)**       **Disease**                 **N**    **Discriminative**    **Controls**                 **N**        **No. of markers**        **Sensitivity/Specificity (%)\***     **Ref.**
  ----------------------- -------------------------- ------- ----------------------- --------------------------- ------- ------------------------------- ------------------------------------- ------------------------
  Caldeira (2011)         Asthma                       35              \+            Controls                      15                  28                CVV: 88%                              \[[@B17]\]
  Caldeira (2012)         Asthma                       32              \+            Controls                      27                   9                98/93                                 \[[@B18]\]
  Dallinga (2010)         Asthma                       63              \+            Controls                      57                8 to 22             89 - 100/95 - 100                     \[[@B19]\]
  Dragonieri (2007)       Mild asthma                  10              \+            Controls                      10                 N.S.               CVV: 100% (M-distance 5.32)           \[[@B10]\]
  Severe asthma           10                           \+           Controls         10                           N.S.     CVV: 90% (M-distance 2.77)                                          
  Fens (2009)             Asthma                       20              \+            Non-smoking controls          20                 N.S.               CVV: 95% (p \< 0.001)                 \[[@B15]\]
  Asthma                  20                           \+       Smoking controls     20                           N.S.        CVV: 93% (p \< 0.001)                                            
  Ibrahim (2011)          Asthma                       35              \+            Non-smoking controls          23                  15                CVV: 83% (PPV: 0.85, NPV: 0.89)       \[[@B20]\]
  Montuschi (2010)        Asthma                       27              \+            Controls                      24                 N.S.               DP: 88%                               \[[@B22]\]
  Timms (2012)            Asthma                       20              \+            Controls                       7                 N.S.               CVV: 70% (p = 0.047)                  \[[@B32]\]
  COPD                    17                           \+           Controls         7                            N.S.    M-distance: 3.601 (p \< 0.01)                                        
  Cristescu (2011)        Emphysema                    43              \-            (Former) smoking controls     161                  1                AUC: 0.56 (CI: 0.45-0.66)             \[[@B26]\]
  Basanta (2010)          COPD                         20              \+            Smoking controls               6                 N.S.               88/81                                 \[[@B25]\]
  Fens (2009)             COPD                         30              +/−           Smoking controls              20                 N.S.               CVV: 66% (p \< 0.01)                  \[[@B15]\]
  COPD                    30                           \-     Non-smoking controls   20                           N.S.              CVV: N.S.                                                  
  Hattesohl (2011)        COPD                         23              +/−           Controls                      10                 N.S.               CVV: 68% (p \< 0.001)                 \[[@B28]\]
  Hauschild (2012)        COPD                         84              \+            Controls                      35                  120               87 - 98/71 - 86                       \[[@B29]\]
  Phillips (2012)         COPD                         119             \+            Controls                      63                 N.S.               79/64                                 \[[@B31]\]
  Van Berkel (2010)       COPD                         50              \+            Controls                      29                6 to 13             98 - 100/88 - 100                     \[[@B33]\]
  COPD (validation)       16                           \+     Controls (validation)  16                             6                100/81                                                    
  Robroeks (2010)         CF                           48              \+            Controls                      57                  22                100/100                               \[[@B14]\]
  Bajtarevic (2009)       LC                           65              \+            Controls                      31               15 to 21             71 - 80/100 - 100                     \[[@B41]\]
  D'Amico (2010)          LC                           28              \+            Controls                      36                 N.S.               85/100                                \[[@B44]\]
  Di Natale (2003)        LC                           35              \+            Controls                      18                 N.S.               100/94                                \[[@B11]\]
  Dragonieri (2009)       NSCLC                        10              \+            Controls                      10                 N.S.               CVV: 90% (M-distance 2.96)            \[[@B12]\]
  Gaspar (2009)           LC                           18              \+            Controls                      10                  10                100/100                               \[[@B46]\]
  Gordon (1985)           LC                           12              \+            Controls                       9                  22                DP \> 80%                             \[[@B47]\]
  Ligor (2009)            LC                           65              +/−           Controls                      31                   8                51/100                                \[[@B49]\]
  Machado (2005)          LC                           14              \+            Controls                      20                 N.S.               CVV: 72% (M-distance: 3.25)           \[[@B13]\]
  Mazzone (2007)          NSCLC                        49              \-            Controls                      21                 N.S.               57/78                                 \[[@B50]\]
  Peng (2009)             LC                           40              \+            Controls                      56                  42                2 PCA clusters: 100% discrimination   \[[@B52]\]
  Peng (2010)             PLC                          30              \+            Controls                      22                  33                2 PCA clusters: 100% discrimination   \[[@B53]\]
  Phillips (2003)         PLC                          67              \+            Controls                      41                   9                85/81                                 \[[@B7]\]
  Phillips (2007--2008)   PLC                          193             \+            Controls                      211              16 to 30             85 - 85/80 - 81                       \[[@B55]\], \[[@B56]\]
  Poli (2010)             NSCLC                        40              \+            Controls                      38                   7                90/92                                 \[[@B59]\]
  Steeghs (2007)          LC                           11              \+            Controls                      57                   2                AUC: 0.81                             \[[@B64]\]
  Westhoff (2009)         LC                           32              \+            Controls                      54                  23                100/100                               \[[@B67]\]
  Chapman (2012)          MPM                          10              \+            Controls                      32                 N.S.               90/91                                 \[[@B68]\]
  Dragonieri (2012)       MPM                          13              \+            Controls                      13                 N.S.               CVV: 85% (p \< 0.001)                 \[[@B69]\]
  Phillips (2007)         Patients suspected of TB     42              \+            Controls                      59               N.S. (≈7)            100/100                               \[[@B77]\]
  Phillips (2012)         Patients with TB             130             +/−           Controls                      121                  8                71/72                                 \[[@B79]\]

\*Sensitivity/Specificity (in %), unless stated otherwise. AUC = Area Under the ROC Curve; CF = Cystic Fibrosis; CI = 95% Confidence interval; COPD = Chronic Obstructive Pulmonary Disease; CVV = Cross-Validated accuracy-Value; DP = Diagnostic Performance; LC = Lung Cancer; M-distance = Mahalanobis-distance; MPM = Malignant Pleural Mesothelioma; N = Sample size; NPV = Negative Predictive Value; N.S. = Not Stated; NSCLC = Non-Small Cell Lung Cancer; PCA = Principal Component Analysis; PLC = Primary Lung Cancer; PPV = Positive Predictive Value; Ref. = Reference; TB = pulmonary Tuberculosis.

###### 

Studies using VOCs profiles for the differential diagnosis of various pulmonary diseases

  **Author (year)**   **Disease I**                  **N**   **Discriminative**  **Disease II**              **N**        **No. of markers**       **Sensitivity/Specificity (%)\***        **Ref.**
  ------------------- ----------------------------- ------- -------------------- -------------------------- ------- ------------------------------ ---------------------------------------- ------------
  D'Amico (2010)      LC                              28             \+          Other lung diseases          28                 N.S.              93/79                                    \[[@B44]\]
  Dragonieri (2007)   Mild asthma                     10            +/−          Severe asthma                10                 N.S.              CVV: 65% (M-distance 1.23)               \[[@B10]\]
  Fens (2009)         Asthma                          20             \+          COPD                         30                 N.S.              CVV: 96% (p \< 0.001)                    \[[@B15]\]
  Fens (2011) \*\*    Fixed Asthma                    21             \+          COPD                         40                 N.S.              85/90 (CVV: 88%, p \< 0.001)             \[[@B27]\]
  Classic Asthma      39                              \+                                                             91/90 (CVV: 83%, p \< 0.001)                                           
  Ibrahim (2011)      Controlled Asthma               17             \+          Uncontrolled asthma          18                  13               89/88 (PPV: 0.89, NPV: 0.88)             \[[@B20]\]
  Timms (2012)        Asthma                          20             \+          COPD                         17                 N.S.              CVV: 70% (p \< 0.05)                     \[[@B32]\]
  Asthma              11                              \+      Asthma with GER    9                                       CVV: 85% (p \< 0.05)                                               
  COPD                8                               +/-      COPD with GER     9                                       CVV: 65 (p \< 0.05)                                                
  Hattesohl (2011)    COPD without AAT deficiency     23            +/-          COPD with AAT deficiency     10                 N.S.              CVV: 58% (M-distance: 2.27)              \[[@B28]\]
  Dragonieri (2009)   LC                              10             \+          COPD                         10                 N.S.              CVV: 85% (M-distance: 3.73)              \[[@B12]\]
  Machado (2005)      LC (validation)                 14            +/-          No LC                        62                 N.S.              71/92                                    \[[@B13]\]
  Mazzone (2007)      LC                              49            +/−          No LC                        94                 N.S.              73/72                                    \[[@B50]\]
  Mazzone (2012)      NSCLC                           83             \+          No LC                        137                N.S.              70/86                                    \[[@B51]\]
  Adenocarcinoma      50                              \+           No LC         137                                            80/86                                                       
  Squamous cell       23                              \+           No LC         137                                            91/73                                                       
  Adenocarcinoma      50                              \+       Squamous cell     22                                             90/83                                                       
  Phillips (1999)     LC                              60            +/−          No LC                        48                  22               72/67                                    \[[@B54]\]
  Phillips (2003)     MLC                             15             \-          No MLC                       91                  9                67/37                                    \[[@B7]\]
  Poli (2005)         NSCLC                           36             \+          No LC                        110                 13               72/94                                    \[[@B57]\]
  Chapman (2012)      MPM                             10             \+          ARD                          18                 N.S.              90/83                                    \[[@B68]\]
  Dragonieri (2012)   MPM                             13             \+          No MPM                       13                 N.S.              CVV: 81% (p \< 0.001)                    \[[@B69]\]
  Hanson (2005)       \+ VAP score                    19             \+          \- VAP score                 19                 N.S.              R^2^ (to standard): 0.81 (p \< 0.0001)   \[[@B72]\]
  Hockstein (2004)    VAP                             13             \+          No VAP                       12                 N.S.              CVV: \>80%                               \[[@B73]\]
  Hockstein (2005)    \+ VAP score                    15            +/−          \- VAP score                 29                 N.S.              CVV: 66-70%                              \[[@B74]\]
  Kolk (2012)         TB                              50             \+          No TB                        50                  7                72/86                                    \[[@B76]\]
  TB (validation)     21                              \+           No TB         50                            7                62/84                                                       
  Phillips (2007)     TB                              23             \+          No TB                        19              N.S. (≈14)           96/79                                    \[[@B77]\]
  Phillips (2010)     TB                             N.S.            \+          No TB                       N.S.             N.S. (≈10)           84/65                                    \[[@B78]\]

\*Sensitivity/Specificity (in %), unless stated otherwise. AAT deficiency = Alpha 1-antitrypsin deficiency; ARD = benign asbestos-related diseases; Classic asthma = Asthmatics with reversible airway obstruction; COPD = Chronic Obstructive Pulmonary Disease; CVV = Cross-Validated accuracy-Value; DP = Diagnostic Performance; Fixed asthma = Asthmatics with fixed airway obstruction; GER = Gastro-Esophageal Reflux; LC = Lung Cancer; M-distance = Mahalanobis-distance; MLC = Metastatic Lung Cancer; MPM = Malignant Pleural Mesothelioma; N = Sample size; NPV = Negative Predictive Value; N.S. = Not Stated; NSCLC = Non-Small Cell Lung Cancer; PPV = Positive Predictive Value; R^2^ = Coefficient of determination; TB = pulmonary Tuberculosis; VAP = Ventilator Associated-Pneumonia. \*\* External validation study of Fens 2009.

Results
=======

Description of included studies
-------------------------------

Seventy-three studies were included of which the characteristics are provided in Table [1](#T1){ref-type="table"}. In total, nine studies described VOCs in asthma, seven in COPD, seven in CF, four compared asthma with COPD or CF, thirty-four in thoracic cancer (of which 6 studies included COPD patients in the control group), and twelve studies described VOCs in other pulmonary diseases. A total of 2,973 healthy controls and 3,952 patients were investigated; 417 asthmatic patients, 527 COPD patients, 188 CF patients, 1,575 lung cancer patients, 33 malignant pleural mesothelioma (MPM) patients, 139 subjects with an abnormal chest radiograph, 579 subjects suspected for pulmonary tuberculosis, and 494 patients with other (pulmonary) diseases (e.g. sarcoidosis, acute respiratory distress syndrome). Various techniques were described to collect and analyze exhaled VOCs. The most commonly used technique was gas chromatography (N = 50), usually combined with MS or FID. Fifteen studies analyzed VOCs using an eNose, whilst thirteen studies used PTR-MS, SIFT-MS, IMS, laser spectroscopy, colorimetric sensor array, and/or GNPs (some studies used multiple techniques). Forty-five studies were conducted in the last five years. An overview of findings per study can be found in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}. The most important findings are summarized below.

Volatile organic compounds in asthma
------------------------------------

Several studies found that an accurate asthma diagnosis was possible using profiles of VOCs (Table [3](#T3){ref-type="table"}). Dragonieri and Fens et al. demonstrated that a VOCs profile could correctly classify asthmatic patients when using an eNose \[[@B10],[@B15]\]. Moreover, Montuschi and colleagues demonstrated that VOCs profiling using an eNose had higher diagnostic performance for asthma than exhaled nitric oxide or lung function \[[@B22]\]. Dallinga and Caldeira et al. demonstrated that VOCs profiling was able to accurately distinguish children with asthma from controls \[[@B17]-[@B19]\]. With respect to differential diagnosis, it was demonstrated that an eNose VOCs profile was able to discriminate between asthma and COPD patients (Table [4](#T4){ref-type="table"}) \[[@B15],[@B32]\]. An external validation study demonstrated that not only 'classical' asthmatic patients (with reversible airway obstruction) but also asthmatic patients with fixed airway obstruction could be distinguished from COPD patients \[[@B27]\]. As these latter two groups usually have similar symptoms and overlapping spirometry, differential diagnosis is often difficult. These findings imply that VOCs profiling is of additional value in the differential diagnosis of asthma and COPD.

Next to diagnosing asthma, VOCs might be useful in the assessment of asthma severity and control. Paredi et al. found elevated levels of exhaled ethane in steroid-naïve asthmatics compared to steroid-treated asthmatics (Table [2](#T2){ref-type="table"}). Furthermore, ethane was higher in patients with severe asthma (FEV~1~ \< 60%), compared to patients with mild asthma (FEV~1~ \> 60%) \[[@B24]\]. In contrast, Dragonieri et al. reported that it was not possible to adequately distinguish mild and severe asthmatics using an eNose profile \[[@B10]\]. Regarding asthma control, higher exhaled pentane levels were found in asthmatic patients with an exacerbation compared to controls. Once the asthma exacerbation subsidized, pentane levels decreased to levels comparable to controls \[[@B23]\]. Moreover, Ibrahim demonstrated that VOCs profiles were able to diagnose sputum eosinophilia and identify patients with poor disease control \[[@B20]\]. Taken together, VOCs profiling might be useful for an asthma diagnosis, for differentiating asthma from COPD, and for assessing asthma control. The usefulness of VOCs profiles in assessing disease severity still needs to be established.

Volatile organic compounds in chronic obstructive pulmonary disease
-------------------------------------------------------------------

Many COPD patients are diagnosed at an advanced stage of the disease, when benefits of interventions such as smoking cessation and drug therapy are less pronounced. An early diagnosis of COPD would be an advantage. Multiple research groups demonstrated that VOC profiles could accurately differentiate COPD patients from healthy (non-) smokers \[[@B25],[@B29],[@B31],[@B33]\]. In contrast, others found a limited performance of VOCs profiles to differentiate COPD patients from (former) smokers \[[@B15],[@B26]\]. Hattesohl et al. demonstrated that eNose derived VOCs profiles were not different between COPD patients with and without an alpha 1-antitrypsin (AAT) deficiency, after internal cross-validation. Moreover, cross-validated VOCs profiles of AAT deficiency patients did not differ after human recombinant AAT therapy \[[@B28]\].

Next to diagnostic purposes, VOCs might be useful to monitor severity and inflammation status in COPD patients. Elevated levels of ethane were found in steroid-naïve COPD patients and patients with low FEV~1~ values compared to steroid-treated patients and patients with higher FEV~1~ values \[[@B30]\]. Fens et al. demonstrated that VOCs profiles were associated with both cell counts and sputum markers of inflammatory cell activation (eosinophilic vs. neutrophilic) in COPD patients \[[@B83]\]. These findings indicate that VOCs profiles might monitor both type and activity of airway inflammation.

Volatile organic compounds in cystic fibrosis
---------------------------------------------

In CF, there is less need for a new diagnostic tool as the sweat chloride test and genetic screening serve as gold standards. However, there is need for new tools regarding early detection of *Pseudomonas (P.) aeruginosa* and prediction and follow-up of exacerbations. Robroeks et al. demonstrated that a VOCs profile could accurately discriminate between CF patients with and without *P. aeruginosa* colonization \[[@B14]\]. Gilchrist et al. showed that exhaled hydrogen cyanide (a marker of *P. aeruginosa*) was elevated in CF children with *P. aeruginosa* colonization compared to CF children without colonization \[[@B36]\]. Accordingly, Enderby et al. demonstrated that exhaled hydrogen cyanide was elevated in children with CF compared to children with asthma \[[@B35]\]. Kamboures et al. demonstrated elevated levels of exhaled sulphides (produced by bacteria such as *P. aeruginosa)* in CF patients compared to controls \[[@B37]\]. In contrast, Shestivska et al. could not demonstrate different levels of exhaled methyl thiocyanate (also a marker of *P. aeruginosa*) in CF patients and controls \[[@B40]\].

Regarding monitoring disease control, McGrath et al. demonstrated that CF patients with an acute exacerbation had lower levels of exhaled isoprene compared to controls \[[@B38]\]. When these patients were treated with antibiotics, their isoprene levels increased to normal \[[@B38]\]. Moreover, elevated ethane levels were found in steroid-naïve CF patients compared to steroid-treated patients \[[@B39]\]. In addition, elevated pentane levels were found in CF patients with an exacerbation \[[@B34]\]. These data demonstrate that VOCs profiling can be useful for assessment and follow-up of exacerbations, and for a rapid detection of *P. aeruginosa* in CF patients.

Volatile organic compounds in thoracic oncology
-----------------------------------------------

The majority of lung cancer (LC) patients studied had non-small cell lung cancer (Table [1](#T1){ref-type="table"}). Several studies demonstrated that a combination of VOCs, identified by GC-MS, could differentiate LC patients from controls \[[@B7],[@B41],[@B46],[@B47],[@B49],[@B52],[@B53],[@B55],[@B56],[@B59]\]. In general, the number of VOCs per model ranged from 7 to 33, with a sensitivity of 50-100% and a specificity of 80-100% (Table [3](#T3){ref-type="table"}). These studies, together with studies investigating single VOCs, revealed that the discriminative VOCs were predominantly alkanes (e.g. pentane, butane, propane), alkane derivates (e.g. propanol, multiple aldehydes) and benzene derivates (e.g. ethyl-, propylbenzene) (Table [2](#T2){ref-type="table"}) \[[@B42],[@B43],[@B45],[@B48],[@B57],[@B59]-[@B63],[@B65],[@B66]\]. Although most VOCs levels were elevated, certain levels (e.g. of isoprene) were decreased in patients compared to controls \[[@B41],[@B58],[@B66]\]. The diagnostic potential of VOCs profiles in LC was also demonstrated by groups that used eNose and other sophisticated techniques \[[@B11]-[@B13],[@B44],[@B51]-[@B53],[@B64],[@B67]\]. Moreover, breath profiles were different in patients with dissimilar histology (adenocarcinoma vs. squamous cell carcinoma) \[[@B51]\]. Besides, Peng et al. demonstrated distinct VOCs profiles in patients with lung, colon, breast, and prostate cancer \[[@B53]\]. The important findings of VOC signatures of different cancer types, need to be confirmed in wider clinical studies.

Multiple studies investigated the potential of VOCs to discriminate between LC and other pulmonary diseases. Not single compounds (such as ethane), but a combination of multiple VOCs was able to distinct LC patients from patients with non-cancer pulmonary diseases (such as COPD, pleurisy, idiopathic fibrosis) with a reasonable accuracy (Table [4](#T4){ref-type="table"}) \[[@B12],[@B13],[@B44],[@B50],[@B57],[@B62]\]. Phillips et al. demonstrated that primary LC could be reasonably diagnosed in subjects with an abnormal chest radiograph \[[@B7],[@B54]\]. However, VOCs had limited predictive value to stage LC patients \[[@B7],[@B63],[@B84]\].

Two studies described the potential of VOCs in evaluating treatment in LC patients. Poli et al. demonstrated that VOCs levels, except for isoprene, were unaffected one month after surgical resection of the tumor \[[@B58]\]. After three years, several VOCs either increased (e.g. pentane) or decreased (e.g. isoprene) compared to baseline \[[@B58]\]. However, most post-surgical VOCs levels remained higher compared to levels of controls. Likewise, Crohns et al. were not able to detect changes of pentane levels after radiotherapy, although they did demonstrate that higher pre-treatment levels predicted better survival \[[@B43]\].

Malignant pleural mesothelioma (MPM) is a rare tumor mainly caused by asbestos exposure. VOCs profiles were able to diagnose MPM in a group of subjects with long-term professional asbestos exposure \[[@B68],[@B69]\]. Moreover, de Gennaro et al. distilled cyclohexane as possible marker of MPM \[[@B70]\].

Smoking status can be an important influencing factor, especially in patients with LC and COPD. Smoke contains profuse amounts of VOCs and is associated with alterations in exhaled VOCs patterns. As high background of external VOCs caused by smoking can influence the accuracy of the diagnostic profile, most studies performed in LC and COPD took smoking status into account in their analysis \[[@B15],[@B25],[@B27],[@B31],[@B33],[@B43],[@B50],[@B53]-[@B55],[@B59],[@B65]\].

Volatile organic compounds in other pulmonary diseases
------------------------------------------------------

VOCs were also studied in critically ill patients with acute respiratory distress syndrome (ARDS). Lower isoprene levels and elevated pentane levels were reported in ARDS patients compared to controls \[[@B81],[@B82]\]. These findings are in line with the findings that critically ill patients with ventilator-associated pneumonia (VAP) had decreased isoprene levels and increased pentane levels compared to patients without pneumonia \[[@B82]\]. In addition, VOCs profiles generated with the eNose had potential to diagnose this form of pneumonia \[[@B72]-[@B74]\].

Kanoh et al. demonstrated that exhaled ethane was elevated in patients with an interstitial lung disease (including sarcoidosis and idiopathic pulmonary fibrosis) compared to controls, with highest levels in those with an active and progressive disease \[[@B75]\]. A small VOC, 2-pentylfuran, was commonly present in breath of patients with a chronic pulmonary disease (including asthma and CF) with *Aspergillus fumigatus* in their respiratory specimens, whereas this VOC was not detected in breath of controls \[[@B71]\]. Syhre et al. demonstrated elevated levels of exhaled methyl nicotinate (a volatile metabolite produced by *M. tuberculosis*) in patients with pulmonary tuberculosis (TB) compared to healthy controls \[[@B80]\]. In a group of patients with suspicion of TB, VOC patterns were able to distinguish patients with TB from those without active TB and healthy controls with a reasonable accuracy (Table [4](#T4){ref-type="table"}) \[[@B76]-[@B79]\].

Discussion
==========

Conclusions from this review
----------------------------

A substantial increase in clinical studies on VOCs in pulmonary diseases was observed in the last decade. Initial studies on VOCs identified biomarkers in a traditional way by focusing on single compounds based on biological insight. Levels of several VOCs were demonstrated to be distinct in people with a pulmonary disease compared to controls. These markers mainly included alkanes for asthma and COPD; alkanes, alkenes and alkene-derivates for CF and analogous compounds plus benzene derivates and aldehydes in lung cancer. Due to overlap in markers, one may argue that a disease specific biomarker is not discovered yet. For example, ethane was not only elevated in asthmatic patients, but also in COPD and CF patients. Similarly, decreased levels of isoprene were found in both children with CF, asthmatic patients, lung cancer patients and in patients with ARDS. Despite the lack of a single discriminative biomarker, these studies did demonstrate that exhaled breath of patients with a particular lung disease is distinct from healthy controls. This finding evolved in a new hypothesis that pulmonary diseases are characterized by a distinctive breath-print that is not based on single markers, but on a profile of numerous VOCs. Instead of a knowledge based strategy, recent studies mainly support an inductive strategy to discover disease-specific VOCs profiles. Owing to recent technical and analytical advancements, hundreds of VOCs can be analyzed to characterize the breath-print of a pulmonary disease. Various research groups demonstrated that, either by using the eNose or GC, VOCs profiles of patients with several pulmonary diseases could be well distinguished from VOCs profiles of controls. Moreover, distinct VOCs profiles were found in patients with dissimilar pulmonary diseases. These promising results pave the way for the development of a non-invasive diagnostic tool based on exhaled VOCs.

Potential applications and advantages of using VOCs into clinical practice
--------------------------------------------------------------------------

Although current research mainly focused on the diagnostic potential of VOCs, there are multiple other conceivable applications of VOCs in the field of pulmonary diseases, such as:

(early) Diagnosing of pulmonary diseases (e.g. early asthma diagnosis in children).

Differential diagnosing (e.g. asthma versus COPD).

Phenotyping within a pulmonary disease (e.g. wheezing phenotypes in children).

Monitoring disease severity and control.

Predicting exacerbations and prognosis of a disease.

Evaluating treatment/surgery (e.g. checking compliance with prescribed medication).

Screening for different diseases in population based studies (e.g. predicting risk).

The advantages of VOCs profiling are evident. Although VOCs can have an exogenous origin, numerous VOCs are formed within the airways as a result of local inflammatory or neoplastic processes. Therefore, the analysis of exhaled VOCs can serve as a direct measure of lung status. Nevertheless, since VOCs are blood-borne they can also reflect other processes in the body and thus may assess different body functions in a flexible manner. Secondly, collection of breath samples is safe, non-invasive and easy to perform even in children and more severe patients. Breath collection does not require skilled medical staff and obtaining large quantities or repeated measurements are not as bothersome for patients compared to e.g. blood sampling, sputum induction or bronchoalveolar lavages. Moreover, the matrix of exhaled breath is less complex than blood or urine, eliminating the need for complicated work-up of samples. Finally, techniques to measure VOCs, such as GC-MS, are very sensitive to detect compounds and techniques such as the IMS allow real-time measurement of compounds in the body.

Challenges before VOCs can be used into clinical practice
---------------------------------------------------------

Although VOCs profiling is a potential clinical tool, considerable work needs to be done before it can be applied into clinical practice. An important step that needs to be taken is extensive validation of the current available VOCs profiles. Next to (external) validation, standardization in collecting and analyzing VOCs is necessary to enhance inter-laboratory comparability. Due to the heterogeneity of the included studies (in study design, sampling and analytical techniques) a variety of results is reported, making it difficult to draw firm conclusions or to calculate an algorithm for the most important compounds in the diverse pulmonary diseases. In the standardization procedure, the influence of potential confounders needs to be explored before considering VOCs as a clinical tool \[[@B48]\]. As described before, exhaled VOCs can arise from various endogenous and exogenous sources. Consequently, numerous environmental-, subject- and analytical factors can influence the exhaled VOCs pattern (Table [5](#T5){ref-type="table"}). For example, air pollution, smoking, eating, drinking and medication use can considerably affect the composition of exhaled VOCs \[[@B85]\]. Also the presence of bacteria can alter exhaled VOCs patterns (hence breath analysis could be used to identify bacterial infections and bacterial-induced diseases). This suggests that these factors should be taken into account when constructing a diagnostic tool on basis of VOCs patterns. Moreover, potential confounders on analytical level should be carefully studied. For example, during the offline-procedure of exhaled VOCs collection, Tedlar bags could release VOCs into the collected breath, and storage onto Tenax columns can disturb the composition of the breath. As the pool of exhaled VOCs arises from multiple endogenous and exogenous sources, the analysis of background samples and standardization of the analysis per technique is necessary. A list of recommendations for measurements composed by experts, as was provided for markers in exhaled breath condensate, will facilitate standardization \[[@B86]\]. Thirdly, more insight is needed in the physiological meaning and biochemical origin of endogenous formed VOCs. However, this might be difficult since, as described before, the origin of VOCs is blood-borne and therefore can be the result of widely different biochemical pathways (so the previously mentioned advantage of VOCs is a disadvantage as well). Fourthly, more research is needed on the potential of VOCs in differential diagnosis and monitoring purposes. Besides these four major 'missions', others aspects of VOCs assessment and analysis can be improved. Although breath samples are easy to collect, the analysis of VOCs is still quite cumbersome and time-consuming and requires trained personnel. Moreover, further refinement of sampling techniques, exploring advanced statistical techniques on the multi-data of VOCs to build diagnostic and prognostic models, and developing new tools that combine the strengths of the eNose (cheap, time efficient), IMS (real-time), and GC-MS (sensitive, compound identification) will facilitate the introduction of VOCs into clinical practice.

###### 

Factors that can influence exhaled VOCs in pulmonary diseases

  **Source**                                                                          **Factor**
  ----------------------------------------------------------------------------------- ------------------------------------------------------------
  Environment                                                                         Ambient VOCs (e.g. by air pollution)
  Temperature of environment                                                          
  Humidity of inhaled and exhaled air                                                 
  Season                                                                              
  Subject                                                                             Clinical characteristics: e.g. age, gender, weight, length
  Nutrition                                                                           
  Tobacco smoking                                                                     
  Medication use                                                                      
  Circadian rhythm                                                                    
  Non-pulmonary chronic diseases (liver impairment, diabetes, presence of bacteria)   
  Breathing pattern: e.g. exhaled flow, minute ventilation, breath hold               
  Overall lifestyle and physical condition                                            
  Analysis                                                                            Time and way of storage
  Pre-concentration                                                                   
  Breath collection: mixed air or alveolar air                                        
  Collection method: e.g. tedlar bags, metal containers                               
                                                                                      Analytical method: e.g. eNose, GC-MS

Conclusions
===========

As the current available tools are not always fulfilling, there is an increasing interest in non-invasive measurement of exhaled VOCs to improve the diagnosis and management of pulmonary diseases. Due to the complex pathophysiology of most pulmonary diseases, current research mainly focused on profiles of VOCs rather than on individual compounds. Promising findings were reported on VOCs profiles that were able to accurately diagnose and monitor various pulmonary diseases. However, multiple constraints including validation and standardization need to be resolved before VOCs can be applied into clinical practice. The rapid progress that is currently made in the field of VOCs will facilitate the imminent introduction of VOCs profiling as a non-invasive, additional tool to assist in diagnosing and monitoring of pulmonary diseases.
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